Skip to main content
. 2019 Dec 11;9(12):e031019. doi: 10.1136/bmjopen-2019-031019

Figure 3.

Figure 3

Cost-effectiveness (CE) acceptability curve. This plot represents the results of a probabilistic sensitivity analysis (for details, see Methods) comparing the cost-effectiveness of pembrolizumab-pemetrexed-platinum versus placebo-pemetrexed-platinum in metastaticnon-small cell lung cancer (NSCLC).